ETF Research Center

IDNA seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering.

FUND BASICS
Category	Global Equities
Fund Sponsor	Blackrock
Website	www.ishares.com
Inception date	Jun 11, 2019
Assets (mns)	$24
Currency	USD
Expense ratio	47 bp
Distributions	Annually

FUND STRUCTURE
Regulation	Open-Ended Fund
Custodian
Weighting	Market Value
Index replication
Uses derivatives	No
Options available	Yes

SECTOR BREAKDOWN

CONSTITUENT BREAKDOWN
No. of constituents	44
Wgt avg mkt cap (mns)	$24,725
Large cap (>$10bn)	33.9%
Mid cap ($2-10bn)	36.2%
Small cap (<$2bn)	29.9%
Developed mkts	100.0%
Emerging mkts	0.0%

TOP TEN HOLDINGS
Total	44.8 %
SEATTLE GENETICS INC	6.6 %
ALNYLAM PHARMACEUTICALS INC	5.3 %
GENMAB A/S	5.2 %
REGENERON PHARMACEUTICALS	4.6 %
SPARK THERAPEUTICS, INC.	4.1 %
MIRATI THERAPEUTICS INC	3.9 %
BRISTOL-MYERS SQUIBB CO	3.8 %
ASTRAZENECA PLC	3.8 %
FIBROGEN INC	3.8 %
TAKEDA PHARMACEUTICAL CO LTD	3.7 %

TOP COUNTRY EXPOSURE
	UNITED STATES	72.5 %
	JAPAN	7.2 %
	SWITZERLAND	5.2 %
	DENMARK	5.2 %
	BRITAIN	3.8 %
	FRANCE	3.2 %
	GERMANY	2.6 %

HISTORICAL PERFORMANCE info

	Custom date range	Compare to
	thru

Standardized Annual Returns (thru January 01)
Year-to-date	1 year	5 years	10 years	Since Incep.
--	--	--	--	0.0%

Market Correlations
versus...	Beta	R-squared
S&P500	--	--
MSCI EAFE	--	--
MSCI Emg. Mkts.	--	--

Technical Indicators
Recent close	$27.04
30d moving avg.	$25.60
Annualized volatility	0.0%
Short interest (ETF)	0.1%
Relative strength (RSI)	70

Liquidity measures
Avg. volume (thou.)	1
Turnover	0.1%
Bid/Ask (% of price)	0.16%
ADV underlying (mns)	$3,427

Distributions

FINDING ALTERNATIVE FUNDS

Below is a list of 20 potential alternatives to the iShares Genomics Immunology and Healthcare ETF based on the alternatives' overlap in portfolio holdings with IDNA. Consider funds with lower expense ratios and/or higher ALTAR Score™ ratings as possible alternatives.

Benchmark ticker:

IDNA

Expense:

47 bp

ALTAR Score™:

-4.8%

ALTERNATIVE ETFs BASED ON OVERLAP WITH IDNA
Ticker	Fund Name	Overlap¹ vs IDNA (%)	Expense ratio (bp)	Savings vs IDNA (bp)	ALTAR Score™ (%)	ALTAR vs IDNA (%)
CNCR	Loncar Cancer Immunotherapy	29.1	79	-32	-3.8	+1.0
XBI	SPDR S&P Biotech ETF	26.4	35	12	-5.0	-0.2
GNOM	Global X Genomics & Biotechnology	24.4	68	-21	-6.4	-1.6
FBT	First Trust NYSE-ARCA Biotechnology	22.4	57	-10	-0.8	+4.0
BTEC	Principal Healthcare Innovators Index	21.9	42	5	-4.5	+0.3
GDNA	Goldman Sachs Motif Human Evolution	21.2	50	-3	1.0	+5.8
BBP	BioShares Biotech Products	18.3	79	-32	-3.9	+0.9
SBIO	ALPS Medical Breakthroughs	17.3	50	-3	-6.1	-1.4
ARKG	ARK Genomic Revolution Multi-Sector	15.8	75	-28	-4.2	+0.6
BBC	Virtus LifeSci Biotech Clinical Trials	15.7	79	-32	-14.3	-9.5
IBB	iShares NASDAQ Biotechnology	15.2	47	0	1.3	+6.1
BBH	VanEck Vectors Biotech	13.1	35	12	5.4	+10.1
IEIH	iShares Evolved U.S. Innovative Healthcare	12.2	18	29	4.8	+9.6
IXJ	iShares S&P Global Healthcare	11.4	46	1	6.5	+11.2
LNGR	Global X Longevity Thematic	9.6	50	-3	3.6	+8.4
FXH	First Trust Health Care Alphadex	8.3	63	-16	7.2	+12.0
ARKK	ARK Innovation	7.5	75	-28	-4.7	+0.1
HDEF	Xtrackers MSCI EAFE High Div Yld Hedged	7.0	20	27	8.5	+13.3
PBE	Invesco Dynamic Biotechnology & Genome	6.8	57	-10	0.0	+4.8
PJP	Invesco Dynamic Pharmaceuticals	6.0	56	-9	9.8	+14.5

¹Overlap is the percentage of holdings by weight that are identical. For example, if Fund A has a 2% position in Apple, Inc. (AAPL) and Fund B has a 5% position, their overlapping position in AAPL is 2%.

Content on this tab for subscribers only**

RESULTS & ESTIMATES

	2014	2015	2016	2017	2018	2019E	2020E
Sales per share	**	**	**	**	**	**	**
Earnings per share	**	**	**	**	**	**	**
Dividends per share	**	**	**	**	**	**	**
Book value per share	**	**	**	**	**	**	**

Sales per share growth		**%	**%	**%	**%	**%	**%
EPS growth		**%	**%	**%	**%	**%	**%

Sales per share growth		**%	**%	**%	**%	**%	**%
EPS growth		**%	**%	**%	**%	**%	**%

OTHER FUNDAMENTAL METRICS

Long term EPS growth est.	**%		Debt-to-equity	**x
Asset turnover	**%		Assets-to-equity	**x

Return on equity

Revision activity*

*Six months ago = 100

Net margins

Compound annual growth rates

Content on this tab for subscribers only

VALUATION METRICS

	2018	2019E	2020E
Price-to-sales	**	**	**
Price-to-earnings	**	**	**
Price-to-cash flow	**	**	**
Price-to-growth	**	**	**
Price-to-book value	**	**	**
Yield	**	**	**

Historical valuation trends

Forward multiple:	iShares Genomics Immunology and Healthcare
Relative to:	S&P500	MSCI EAFE	MSCI Emg. Mkts.	Other ETF:

AVOID

Not worthwhile for most investors. A rating of AVOID is assigned to ETFs with ALTAR Scores in the lowest quintile (the bottom 20%) of their category. Often, funds in this category consist of stocks with little if any history or expectation of profitability, and as a result our fundamentally-driven analysis may not be relevant.

ALTAR Score™

Calculation of ALTAR Score™
Avg. Return on Equity	-23.4	%
Divided by: Fwd. P/BV	5.4	x
Less: Expense ratio	47	bp
Equals: ALTAR Score	-4.8	%

More information on ALTAR Score™

MODERN PORTFOLIO THEORY info

CONSENSUS RECOMMENDATIONS: FUND CONSTITUENTS

COMPOSITE RATING	1.36	CATEGORY AVERAGE	1.54

The composite rating is a weighted average of analysts' consensus recommendations for individual ETF constituents, based on the following scale: BUY = 1; OVERWEIGHT = 1.5, HOLD = 2; UNDERWEIGHT = 2.5; and SELL = 3. Readers are cautioned that because analyst ratings tend to be inflated, the composite score may be more useful as a relative measure of sentiment between funds rather than as a stand-alone recommendation.